医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

LianBio Appoints Susan Silbermann to Board of Directors

2021年10月12日 PM08:00
このエントリーをはてなブックマークに追加


 

SHANGHAI & PRINCETON, N.J.

LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced the appointment of Susan Silbermann to the company’s Board of Directors.

“Susan brings to the board remarkable leadership experience and a strong track record of operational execution across therapeutic areas, drug modalities and geographies,” said Yizhe Wang, Ph.D., Chief Executive Officer of LianBio. “She will be a tremendous asset to LianBio as we continue to advance our diverse pipeline of potentially transformative medicines for patients in China and throughout Asia.”

During a 30 year career at Pfizer, Ms. Silbermann held numerous leadership positions in marketing, commercial development and general management in the U.S. and international markets. Prior to her retirement in May 2021, Ms. Silbermann chaired Pfizer’s Global COVID-19 Task Force. At the same time, Ms. Silbermann served as Pfizer’s Global President, Emerging Markets, where she oversaw operations across marketing, medical, sales, access and government affairs in China, Asia, Latin America, Africa and the Middle East. In this role, she designed and implemented a new innovation-focused organization in China, working in close collaboration with both the central government and the provinces to address their specific healthcare needs.

From 2012 until 2018, Ms. Silbermann served as President and General Manager of Pfizer Vaccines. In this role, Ms. Silbermann was responsible for both the commercial development and operational management of Pfizer’s portfolio of preventative and therapeutic vaccines. She was also a member of the board of Gavi, the Vaccine Alliance from 2017 until 2020. From 2008 until 2012, she was the regional president of Latin America within Pfizer’s Emerging Markets Business Unit where she managed Pfizer’s pharmaceutical operations in this diverse region.

“LianBio is leading the next generation of innovation-focused biotech companies in China,” said Ms. Silbermann. “I look forward to collaborating with the board and LianBio team to continue the important work of bringing therapeutic advances to patients in Asia.”

Ms. Silbermann earned a bachelor’s degree in biology and French from Tufts University, and master’s degrees in international business and French studies from the Stern Graduate School of Business and the Institute of French Studies at New York University.

About LianBio
LianBio is a cross-border biotechnology company on a mission to bring transformative medicines to historically underserved patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. LianBio is establishing an international infrastructure to position the company as a partner of choice with a platform to provide access to China and other Asian markets. For more information, please visit www.lianbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005341/en/

CONTACT

For investor inquiries, please contact:

Elizabeth Anderson, VP Communications and Investor Relations

E: elizabeth.anderson@lianbio.com

T: +1 646 655 8390

For media inquiries, please contact:

Katherine Smith, CanaleComm

E: katherine.smith@canalecomm.com

T: +1 619 849 5378

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Xlear Files Amended Answer to the Government’s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear’s Use as Additional Layer of Protection
  • EpiAxis Therapeutics & Peptilogics Enter Strategic Drug Discovery Partnership
  • BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
  • ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer
  • Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen